ISDA

Deposition Date 2008-02-05

Release Date 2008-05-20

Last Version Date 2024-11-20

Entry Detail

PDB ID:

2VNM

Keywords:

HYDROLASE

Title:

Human BACE-1 in complex with 3-(1,1-dioxidotetrahydro-2H-1,2-thiazin- 2-yl)-5-(ethylamino)-N-((1S,2R)-2-hydroxy-1-(phenylmethyl)-3-(((3-(trifluoromethyl)phenyl)methyl)amino)propyl)benzamide

Biological Source:

Source Organism:

HOMO SAPIENS (Taxon ID: 9606)

Host Organism:

CRICETULUS GRISEUS

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.79 Å

R-Value Free:

0.23

R-Value Work:

0.19

R-Value Observed:

0.19

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:BETA-SECRETASE 1
Gene (Uniprot):BACE1
Mutations:YES
Chain IDs:A
Chain Length:392
Number of Molecules:1
Biological Source:HOMO SAPIENS

UniProt ID:P56817 Pfam ID:PF00026 EC:3.4.23.46

Ligand Molecules

CM8

Primary Citation

Second Generation of Hydroxyethylamine Bace-1 Inhibitors: Optimizing Potency and Oral Bioavailability.

Charrier, N, Clarke, B, Cutler, L, Demont, E, Dingwall, C, Dunsdon, R, East, P, Hawkins, J, Howes, C, Hussain, I, Jeffrey, P, Maile, G, Matico, R, Mosley, J, Naylor, A, O'Brien, A, Redshaw, S, Rowland, P, Soleil, V, Smith, K.J, Sweitzer, S, Theobald, P, Vesey, D, Walter, D.S, Wayne, G.Show

J.Med.Chem. 51 3313 ? (2008)

PMID: 18457381 DOI: 10.1021/JM800138H

Abstact

BACE-1 inhibition has the potential to provide a disease-modifying therapy for the treatment of Alzheimer's disease. Optimization of a first generation of BACE-1 inhibitors led to the discovery of novel hydroxyethylamines (HEAs) bearing a tricyclic nonprime side. These derivatives have nanomolar cell potency and are orally bioavailable.

Legend

Protein

Chemical

Disease

Primary Citation of related structures